NextBioMedical Co

NextBioMedical Co EPS Growth

The EPS Growth of NextBioMedical Co (389650.KQ) as of Nov 20, 2026 is -110.82 %. In the previous year, EPS Growth was 137.65 % — a change of -180.51% (lower).

EPS Growth

-110.82 %

YoY

-180.51%

Last updated:

EPS Growth of NextBioMedical Co is 2025 -110.82 % . EPS Growth of NextBioMedical Co was 2024 137.65 % . It decreases by -180.51% lower compared to the previous year.

The NextBioMedical Co EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2022
65.56 KRW
Jan 1, 2023
-31.22 KRW
Jan 1, 2024
137.65 KRW
Jan 1, 2025
-110.82 KRW
The NextBioMedical Co EPS Growth history
YEAREPS GrowthYoY
-110.82 %-180.51%
137.65 %-540.86%
-31.22 %-147.62%
65.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextBioMedical Co Stock analysis

What does NextBioMedical Co do? NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings. The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care. NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry. NextBioMedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextBioMedical Co stock

EPS Growth of NextBioMedical Co is -110.82 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's NextBioMedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — NextBioMedical Co

All Key Metrics — NextBioMedical Co